Biomarker-stratified efficacy and safety of biologics in systemic lupus erythematosus: a systematic review and meta-analysis - PubMed
7 hours ago
- #Meta-analysis
- #Systemic Lupus Erythematosus
- #Biologics
- Biologics for systemic lupus erythematosus (SLE) show variable treatment responses across trials.
- Baseline biomarkers like serologically active disease and high disease activity predict better response to biologics.
- Serologically active disease showed the strongest predictive value with a risk ratio (RR) of 1.45.
- High baseline SLEDAI ≥10 also predicted response with a RR of 1.22.
- Interferon gene signature (IGS) showed non-significant trends in predicting response.
- Anti-BAFF agents demonstrated consistent benefit with a RR of 1.35.
- Biologics reduced serious adverse events (SAE) but increased herpes zoster risk.
- The study supports using serological markers to guide biologic selection in clinical practice.
- Biologics showed favourable safety profiles overall.